A self-assembled therapeutic dendron-micelle includes a first amphiphilic dendron-coil, a second amphiphilic dendron-coil, and optionally a third amphiphilic dendron-coil, and an encapsulated BRD4 ligand or BRD4 proteolysis targeting chimera. The first and optional third amphiphilic dendron-coils have a therapeutic peptide conjugated thereto. Also included are pharmaceutical compositions containing the dendron-micelles, methods of making the dendron-micelles, and therapeutic methods including administering the dendron-micelles to a subject in need thereof.

Methods and compositions for treating diseases or disorders of the nervous system using promoter-driven Designer Receptor Exclusively Activated by Designer Drugs (DREADDs) and DREADD agonists are disclosed.

Methods and compositions for treating diseases or disorders of the nervous system using promoter-driven Designer Receptor Exclusively Activated by Designer Drugs (DREADDs) and DREADD agonists are disclosed.

This invention relates to clear one-phase liquid formulation vehicles comprising lecithin, MCT, bile salt and water.

An oral film in an individual unit dose for delivery of one or more actives is disclosed herein, the film having a precisely calculated and controlled active dissolution profile. A wide variety of actives may be used, including, for example, clobazam, diazepam, or riluzole. Also disclosed are methods of treating a variety of diseases and conditions, for example, epilepsy and seizures, by administering the oral film disclosed herein.

An oral film in an individual unit dose for delivery of one or more actives is disclosed herein, the film having a precisely calculated and controlled active dissolution profile. A wide variety of actives may be used, including, for example, clobazam, diazepam, or riluzole. Also disclosed are methods of treating a variety of diseases and conditions, for example, epilepsy and seizures, by administering the oral film disclosed herein.

Benzodiazepine derivatives of formula (I): wherein: each of R.sup.1 and R.sup.2 is independently H or halo; R.sup.3 is H, C.sub.1-C.sub.6 alkyl, —NHR.sup.8 or —OR′; either (i) a, c, and e are all bonds, with b, d and f absent; orb, d and f are all bonds, with a, c and e absent; R.sup.4 is H or a group selected from C.sub.1-C.sub.6 alkyl, C.sub.3-C.sub.6 cycloalkyl and 4- to 10-membered heterocyclyl, the group being unsubstituted or substituted; R.sup.5 is H or halo; R.sup.6 is —OR.sup.8, —NR.sup.8R.sup.9 or —R.sup.8; R.sup.7 is H or halo; each of R.sup.8 and R.sup.9 is independently H or a group selected from C.sub.1-C.sub.6 alkyl, C.sub.3-C.sub.6 cycloalkyl and 4- to 10-membered heterocyclyl, the group being unsubstituted or substituted; R′ is H or C.sub.1-C.sub.6 alkyl; and one of V and W is CH and the other is N or CH; and the pharmaceutically acceptable salts thereof are inhibitors of RSV and can therefore be used to treat or prevent an RSV infection.

Benzodiazepine derivatives of formula (I): wherein: each of R.sup.1 and R.sup.2 is independently H or halo; R.sup.3 is H, C.sub.1-C.sub.6 alkyl, —NHR.sup.8 or —OR′; either (i) a, c, and e are all bonds, with b, d and f absent; orb, d and f are all bonds, with a, c and e absent; R.sup.4 is H or a group selected from C.sub.1-C.sub.6 alkyl, C.sub.3-C.sub.6 cycloalkyl and 4- to 10-membered heterocyclyl, the group being unsubstituted or substituted; R.sup.5 is H or halo; R.sup.6 is —OR.sup.8, —NR.sup.8R.sup.9 or —R.sup.8; R.sup.7 is H or halo; each of R.sup.8 and R.sup.9 is independently H or a group selected from C.sub.1-C.sub.6 alkyl, C.sub.3-C.sub.6 cycloalkyl and 4- to 10-membered heterocyclyl, the group being unsubstituted or substituted; R′ is H or C.sub.1-C.sub.6 alkyl; and one of V and W is CH and the other is N or CH; and the pharmaceutically acceptable salts thereof are inhibitors of RSV and can therefore be used to treat or prevent an RSV infection.

The present disclosure relates to a compound derivative containing a 6-7 bicyclic ring and use thereof. The compound according to the present invention can be effectively used in the prevention or treatment of diseases caused by PRMT5 by acting as a PRMT5 inhibitor.

Compositions for intranasal delivery of benzodiazepines, such as diazepam, midazolam, and lorazepam and methods for their use to treat and prevent seizures in pediatric subjects aged 2-5, inclusive. Compositions for rapid therapeutic onset with a decreased incidence and/or severity of adverse effects after administration and methods of improving patient compliance with a prescribed treatment regimen.